Your Journey To Health
GlobeStar Therapeutics Corporation (OTCQB: GSTC) is a pioneer in the field of Multiple Sclerosis and other diseases. Our transformative therapies for the management of chronic neurodegenerative diseases are life-changing. Our patented therapies introduce a formulation of previously approved drugs which have been shown in clinical trials to improve the quality of life for these patients.
Are you a GlobeStar investor or interested in becoming one? Learn more about us and the benefits that come from joining our team.
GlobeStar Therapeutics Corporation (OTCBB: GSTC) is an American biotechnology company originally organized in 2011, headquartered in Houston, Texas with offices in the State of Washington, focused on developing innovative therapies for people with serious and life-threating rare disorders.
The Company patented and sold for $10 million of preferred shares a treatment for peripheral artery disease (PAD) called LiprostinTM followed by acquiring an exclusive license for a patented method of treating neurodegenerative diseases such as Multiple Sclerosis by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration and treating neurodegeneration.
We are in discussions with several contract research organizations to assist with our submission of new drug application for global marketing.
Years of Experience
In The News
As a publicly traded company, GlobeStar provides news on its operations through press release distributors like business wire, but it provides the same news here in an expanded format with links to all of the initial released locations and expanded images. this conforms to regulation FD disclosure requirements.
While there are many people all over the world who battle against neurodegenerative diseases every single day, many do not know what they are, and what the correct definition of them is. Therefore, it is important to know how to identify these diseases and the...
AngioSoma, Inc., Soon To Be GlobeStar Therapeutics Corporation, Retains Sichenzia Ross Ference, LLP As Outside Securities Counsel
Law Firm Selected Because of Their Commitment to Excellence and Securities Expertise RICHLAND, WA / ACCESSWIRE / June 9, 2021 / AngioSoma, Inc. (OTC PINK:SOAN) has selected Sichenzia Ross Ference, LLP as its outside securities counsel. Sichenzia Ross Ference, LLP was...
Putting together a care plan is essential for everyone, but for a recently diagnosed MS patient, it can be, literally, a lifesaver. It is important to understand their wishes and desires while this is all fresh to them. If you didn’t do a care plan early on – then...